153 related articles for article (PubMed ID: 20646630)
1. [Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].
Liu N; Niu Y; Wang SL; Yu Q; Zhang RJ; Liu TJ
Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1403-7. PubMed ID: 20646630
[TBL] [Abstract][Full Text] [Related]
2. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
3. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
[TBL] [Abstract][Full Text] [Related]
4. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
5. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
9. Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast.
Lester T; Wang J; Bourne P; Yang Q; Fu L; Tang P
Ann Clin Lab Sci; 2009; 39(1):17-24. PubMed ID: 19201736
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin profiles of male breast cancers.
Ciocca V; Bombonati A; Gatalica Z; Di Pasquale M; Milos A; Ruiz-Orrico A; Dreher D; Folch N; Monzon F; Santeusanio G; Perou CM; Bernard PS; Palazzo JP
Histopathology; 2006 Oct; 49(4):365-70. PubMed ID: 16978199
[TBL] [Abstract][Full Text] [Related]
13. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype.
Wang J; Liu Y; Ji R; Gu Q; Zhao X; Liu Y; Sun B
Hum Pathol; 2010 Aug; 41(8):1186-95. PubMed ID: 20381828
[TBL] [Abstract][Full Text] [Related]
15. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
Zhang R; Zhang H; Wei H; Luo X
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
[TBL] [Abstract][Full Text] [Related]
16. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
[TBL] [Abstract][Full Text] [Related]
17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
18. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
19. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
20. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]